Longitudinal profile of estrogen-related thrombotic biomarkers after cessation of combined hormonal contraceptives.
Justine Hugon-Rodin, Pierre Fontana, Antoine Poncet...
https://pubmed.ncbi.nlm.nih.gov/37939264/Actively Recruiting
Led by University Hospital, Geneva · Updated on 2026-04-29
30
Participants Needed
1
Research Sites
12 weeks
Total Duration
Uterine fibroids and endometriosis are common conditions among women of reproductive age that can cause pelvic pain and abnormal uterine bleeding. This research evaluates the effects of a novel combined hormonal therapy called Ryeqo, which contains a GnRH antagonist Relugolix along with low-dose estradiol and progesterone, on blood clotting markers to estimate the risk of venous thromboembolism VTE. Understanding this risk could help tailor hormonal treatments based on each womans personal health profile. Ryeqo is taken as an oral pill containing 40 mg of Relugolix combined with 1 mg estradiol and 0.5 mg norethisterone acetate. The treatment suppresses ovulation while maintaining low but steady hormone levels to reduce symptoms and side effects. The study involves two visits before starting Ryeqo and three months after treatment begins. Blood samples and questionnaires on demographics and clinical symptoms are collected at both visits to monitor changes in hemostasis parameters. Participants will undergo blood tests measuring various coagulation markers such as activated protein C resistance, sex hormone-binding globulin, and thrombin generation at baseline and after three months of treatment. Researchers will analyze these to assess any changes linked to VTE risk. The total study duration for each participant is three months, during which safety and symptom questionnaires are also completed to monitor effects and tolerability of the therapy.
CONDITIONS
The Impact of a Novel GnRH Antagonist With Add-back Therapy for Treatment of Uterine Fibroids and Endometriosis on Hemostasis Parameters
M
Manuela Viviano, MD
J
Justine Hugon-Rodin
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University Hospital, Geneva
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 3 months
Participants receive the Ryeqo oral hormonal treatment containing a GnRH antagonist with add-back therapy for uterine fibroids or endometriosis. Hemostasis markers are measured to evaluate the treatment's impact on blood clotting factors.
2 visits (baseline and after 3 months of treatment)
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Justine Hugon-Rodin, Pierre Fontana, Antoine Poncet...
https://pubmed.ncbi.nlm.nih.gov/37939264/University Hospital, Geneva
Lead Sponsor